Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Johan Areberg"'
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 6, Pp 1012-1020 (2023)
Abstract Polymorphism of the CYP2D6 gene leads to substantial interindividual variability in CYP2D6 enzyme activity. Despite improvements in prediction of CYP2D6 activity based on genotype information, large interindividual variability within CYP2D6
Externí odkaz:
https://doaj.org/article/d6f63e0330054e3e8fc2ff41f45e2af8
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 9, Pp 983-993 (2021)
Abstract The cytochrome P450 (CYP) 2D6 enzyme exhibits large interindividual differences in metabolic activity. Patients are commonly assigned a CYP2D6 phenotype based on their CYP2D6 genotype, but there is a lack of consensus on how to translate gen
Externí odkaz:
https://doaj.org/article/83eb35e998554e1abe637b04607a27ce
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 9, Pp 983-993 (2021)
Frederiksen, T, Areberg, J, Schmidt, E, Stage, T B & Brøsen, K 2021, ' Cytochrome P450 2D6 genotype–phenotype characterization through population pharmacokinetic modeling of tedatioxetine ', CPT: Pharmacometrics & Systems Pharmacology, vol. 10, no. 9, pp. 983-993 . https://doi.org/10.1002/psp4.12635
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 9, Pp 983-993 (2021)
Frederiksen, T, Areberg, J, Schmidt, E, Stage, T B & Brøsen, K 2021, ' Cytochrome P450 2D6 genotype–phenotype characterization through population pharmacokinetic modeling of tedatioxetine ', CPT: Pharmacometrics & Systems Pharmacology, vol. 10, no. 9, pp. 983-993 . https://doi.org/10.1002/psp4.12635
The cytochrome P450 (CYP) 2D6 enzyme exhibits large interindividual differences in metabolic activity. Patients are commonly assigned a CYP2D6 phenotype based on their CYP2D6 genotype, but there is a lack of consensus on how to translate genotypes in
Publikováno v:
Clinical Trials. 18:505-510
Background The use of electronic-based devices to measure and to improve adherence of subjects in clinical trials is increasing. AiCure has developed a mobile technology that is claimed to provide visual confirmation of drug ingestion. While there is
Autor:
Trine Frederiksen, Johan Areberg, Arash Raoufinia, Ellen Schmidt, Tore Bjerregaard Stage, Kim Brøsen
Publikováno v:
Clinical pharmacology and therapeutics.
Accurate prediction of CYP2D6 phenotype from genotype information is important to support safe and efficacious pharmacotherapy with CYP2D6 substrates. To facilitate accurate CYP2D6 genotype-phenotype translation, there remains a need to investigate t
Autor:
Anders Ettrup, Elmars Rancans, Mads Dalsgaard, Johan Areberg, Janos Zambori, Ioana Florea, Corine Baayen
Publikováno v:
International Clinical Psychopharmacology
Supplemental Digital Content is available in the text.
This 7-day randomized, double-blind, placebo-controlled fixed-dose study (NCT03766867) explored the potential for accelerating the onset of antidepressant efficacy of single-dose intravenous
This 7-day randomized, double-blind, placebo-controlled fixed-dose study (NCT03766867) explored the potential for accelerating the onset of antidepressant efficacy of single-dose intravenous
Publikováno v:
Frederiksen, T, Smith, R L, Wollmann, B M, Areberg, J & Molden, E 2021, ' Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring Data ', Clinical Pharmacokinetics, vol. 60, no. 11, pp. 1475-1486 . https://doi.org/10.1007/s40262-021-01029-7
Clinical Pharmacokinetics
Clinical Pharmacokinetics
Introduction Vortioxetine is an antidepressant primarily metabolized by the polymorphic enzyme cytochrome P450 (CYP) 2D6. A population pharmacokinetic (popPK) model of vortioxetine and its CYP2D6-dependent metabolite was recently published. Objective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4c2219e990ad44f794b91b8a588049c
https://findresearcher.sdu.dk:8443/ws/files/194772021/Frederiksen_2021_Validation_of_a_population_pharmaco.pdf
https://findresearcher.sdu.dk:8443/ws/files/194772021/Frederiksen_2021_Validation_of_a_population_pharmaco.pdf
Publikováno v:
Advances in Therapy
Introduction Major depressive disorder (MDD) is associated with a significant burden of disease in China. Awareness and better access to treatments could help alleviate the burden associated with MDD. Because variations have been observed in the phar
Publikováno v:
Clinical Pharmacology and Therapeutics
Frederiksen, T, Areberg, J, Schmidt, E, Stage, T B & Brøsen, K 2021, ' Quantification of In Vivo Metabolic Activity of CYP2D6 Genotypes and Alleles through Population Pharmacokinetic Analysis of Vortioxetine ', Clinical Pharmacology and Therapeutics, vol. 109, no. 1, pp. 150-159 . https://doi.org/10.1002/cpt.1972
Frederiksen, T, Areberg, J, Schmidt, E, Stage, T B & Brøsen, K 2021, ' Quantification of In Vivo Metabolic Activity of CYP2D6 Genotypes and Alleles through Population Pharmacokinetic Analysis of Vortioxetine ', Clinical Pharmacology and Therapeutics, vol. 109, no. 1, pp. 150-159 . https://doi.org/10.1002/cpt.1972
Assignment of CYP2D6 phenotype from genotype data can be challenging and despite efforts to standardize translation, there is currently no universally accepted method. To facilitate standardization, there remains a need to precisely quantify the in v
Publikováno v:
Clinical Pharmacokinetics
Vortioxetine is a novel antidepressant with multimodal activity currently approved for the treatment of major depressive disorder. Vortioxetine is orally administered once daily at 5- to 20-mg doses. The pharmacokinetics of vortioxetine are linear an